Skip to main content

Table 1 Characteristics of patients with relapsing polychondritis in present study and previous series

From: Clinical patterns and the evolution of relapsing polychondritis based on organ involvement: a Chinese retrospective cohort study

Clinical features Present study Ferrada et al., 2018 [8] Dion et al., 2016 [27] Lin DF et al., 2016a [7] Oka H et al., 2014 [30] Mathew et al., 2012 [11] Trentham et al.,1998 [13] Zeuner et al., 1997 [9] Michet et al., 1986[16] McAdam et al., 1976b [14]
No. of patients 126 304 142 158 239 43 66 62 112 159
Country North China International France South China Japan USA USA German USA USA
Study design Retro Survey Retro Retro Survey Retro Retro Survey Retro Retro + Liter
Demographic characteristics           
Sex, F/M 60/66 263/41 86/56 65/93 112/127 23/20 49/17 26/36 55/57 76/83
Mean age at onset, years 47.1 NA 43.5 NA 52.7 NA NA NA NA NA
Mean age at diagnosis, years 47.8 43.2 NA 45.3 NA 43 46 46.6* 51* 43.8
Follow-up, months 18 (1–153) NA 156! NA NA NA 96! 11! 72 (1–240) 4.3 !
Median delay, months 5 (0–132) NA 12 (0–300) 14 (0.3–168) NA 38.4** 34.8** NA NA NA
Clinical features, n (%)           
Auricular chondritis 75 (59.6) 262 (86.2) 127 (89.4) 107 (67.7) 187 (78.2) 38 (88.4) 62 (93.9) 58 (93.5) 95 (84.8) 141 (88.7)
Laryngotracheal 61 (48.4)¶ NA 71 (50.0)§ 109 (68.9) 119 (49.8)‡ 16 (37.2) 44 (66.7) 19 (30.6) 53 (47.3) 89 (55.9)
Laryngeal 20 (15.9) 180 (59.2) 61 (43.0) 45/128 (35.2)† 47 (19.7) NA NA NA 19 (16.9) NA
Tracheobronchial 52 (41.3) 225 (74.0) 32 (22.5) NA 97 (40.6) NA NA NA NA NA
Ocular inflammation 34 (26.9) 151 (49.7) 80 (56.3) 70 (44.3) 109 (45.6) 23 (53.5) 37 (56.1) 31 (50.0) 57 (50.9) 104 (65.4)
Fever 26 (20.7) NA 43 (30.3) NA NA NA NA 15 (24.2) 44 (39.3) NA
Nasal chondritis 22 (17.5) 193 (63.5) 89 (62.7) 85 (53.8) 94 (39.3) 15 (34.8) 32 (48.5) 35 (56.5) 60 (53.6) 115 (72.3)
Arthritis 23 (18.3) 250 (82.2) 47 (33.1) 88 (55.7) 92 (38.5) 26 (60.5) 56 (84.8) 33 (53.2) 58 (51.8) 121 (76.1)
Hearing loss 15 (11.9) 104 (34.2) 39 (27.5) 39 (24.7) 52 (21.8) 16 (37.2) 28 (42.4) 12 (19.4) 29 (25.9) 65 (40.9)
Costochondritis 7 (5.6) 143 (47.0) 57 (40.1) 23 (14.6) NA NA NA NA NA 58 (36.5)
Renal involvement 0 (0) NA 0 (0) 4/134 (2.5)† 16 (6.7) 1 (2.3) NA 4 (6.5) 16 (14.3) NA
Neurological involvement 6 (4.8) NA 17 (11.9) 8/69 (11.6) 23 (9.6) NA NA 6 (9.7) NA 5 (3.1)
Skin involvement 2 (1.6) NA 40 (28.2) 17/37 (45.9)† 32 (13.4) NA 25 (37.9) 15 (24.2) 31 (27.7) 26 (16.4)
Valvulopathy 1 (0.8) NA 31 (21.8) 3/98 (3.1)† 5 (2.1)^ NA 5 (7.6) 0 (0) 7 (6.3) 14 (8.8)
Arrhythmia 13 (10.3) NA 13 (9.2) 1/98 (1.0)† 0 (0)^ NA NA 2 (3.2) NA NA
MDS 1 (0.8) NA 12 (8.2) 0 (0) 4 (1.7) NA NA 4 (6.5) NA NA
Autoimmune diseases 4 (3.2%) NA 31 (21.8) 17 (10.8) 11 (4.6) 11 (25.6) 13 (19.7) 22 (35.5) 38 (33.9) NA
  1. Data are presented as n (%).Retro, retrospective; Liter, literature review; NA, not available
  2. aA retrospective review of RPC patients in one medical center in south China and cases reported in Chinese literatures
  3. bAmong 159 patients, 23 were followed up in the author’s center, the remaining 136 patients were cited from literature
  4. *Median age at diagnosis
  5. **Mean delay
  6. !Mean follow-up duration
  7. #Sixty-four percent presented symptoms for more than 5 years before diagnosis
  8. Laryngotracheal involvement was seen in 61 patients (48.4%), indicating 11 patients presented both laryngeal and tracheobronchial involvement
  9. §Laryngotracheal involvement was seen in 71 patients (50%), indicating 22 patients presented both laryngeal and tracheobronchial involvement
  10. Laryngotracheal involvement in 119 patients (50%), indicating 35 patients presented both laryngeal and tracheobronchial
  11. Denominator represents the total number in the category where datas were missing
  12. ^Data were extracted from another study conducted by the same authors [31]